The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1698
March 18, 2024
View Complete Issue         Table of Contents 2019 
Issue 1698
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma
March 18, 2024 (Issue: 1698)
The FDA has approved Airsupra (AstraZeneca), a metered-dose inhaler containing the short-acting beta2-agonist (SABA) albuterol and the inhaled corticosteroid (ICS) budesonide, for use as needed for treatment or prevention of bronchoconstriction...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1698
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.